Tech Company Inital Public Offerings
Foghorn Therapeutics IPO
Foghorn Therapeutics, operating out of Cambridge, debuted as a public company on 10/22/2020.
Transaction Overview
Company Name
Announced On
10/22/2020
Transaction Type
IPO
Amount
$120,000,000
Proceeds Purpose
Management says it will use the net proceeds from the IPO as follows:to advance FHD-286, including our planned Phase 1 clinical trials for AML and uveal melanoma;to advance FHD-609, including our planned Phase 1 clinical trial for synovial sarcoma;for other research and development activities, including continued development of our Gene Traffic Control platform; andthe remainder, if any, for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
100 Binney St. 610
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
A Flagship Pioneering company, Foghorn Therapeutics (Nasdaq: FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adrian Gottschalk
Chief Financial Officer
Tess Cameron
Chief Medical Officer
Samuel Agresta
Vice President
Steve Bellon
Vice President
Ho Chan
Vice President
David Millan
Browse more venture capital transactions:
Prev: 10/22/2020: Anyscale venture capital transaction
Next: 10/22/2020: Resurface Labs venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs